Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received approval from China's National Medical Products Administration for the investigational new drug application of SKB118, according to a Wednesday Hong Kong bourse filing.
The company said the PD-1/VEGF bispecific antibody is intended for the treatment of advanced solid tumors.
The approval clears the company to begin clinical trials for the drug candidate in China, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.